Incyte Corporation · INCY · Next earnings

Incyte Corporation reports Tuesday, Oct 27, 2026

INCY reports before market open with consensus EPS at $-3.31 and revenue at $1.47B. Last quarter: Incyte Q1 Revenue Beats on 21% Growth, Pipeline Catalysts Accelerate Into 2026 Launches

Reports Before market open37 days awayDate estimated Healthcare

What the street expects

Consensus for the coming report
Consensus EPS $-3.31 Calendar consensus
Consensus revenue $1.47B Calendar consensus
Report date Oct 27, 2026 Tuesday, date estimated
Session Before market open 37 days away

Where INCY left off: FY2026 Q1

Full report

Incyte Q1 Revenue Beats on 21% Growth, Pipeline Catalysts Accelerate Into 2026 Launches

EPS surprise +35.1% Reported $1.81 vs $1.34
Revenue surprise +4.7% Reported $1.27B vs $1.22B
Stock move +2.1% Event window
Subsequent drift -0.4% Up to 20 sessions

Full-year 2026 revenue guidance was reaffirmed at $4.77-$4.94 billion, implying 10-13% top-line growth, with non-Jakafi core sales tracking toward ~30% growth at the midpoint. Guidance sentiment was maintained from the prior quarter.

What to watch on the call

Carried forward from the last transcript

Risks management flagged

  • Regulatory approval uncertainty across multiple pending indications including Jakafi XR, Opzelura EU AD, and povorcitinib
  • Clinical trial timelines and potential setbacks, including a pneumonitis safety signal requiring review for the 734 program
  • Reliance on continued Jakafi growth while transitioning to a broader portfolio, with generic competition looming around 2028
  • Competitive pressure in dermatology and oncology markets
  • Potential expense pressure from new leadership and an expanded commercial organization

Questions analysts left open

  • Details of the 989 dose-escalation design and flexibility for ET and MF trials
  • Impact of the new CFO on expense discipline and capital allocation
  • Enrollment pause and safety signals for 734 regarding pneumonitis
  • Timing and potential acceleration of ruxolitinib combination studies
  • Competitive landscape for Opzelura in the non-steroidal topical market

Ask FN2 about INCY next report

Transcript, numbers and history already loaded
What should I watch for in INCY's next earnings report?How did INCY guide last quarter, and is consensus above or below that?Give me the bull and bear case going into INCY earnings.

Free account. Your question opens in FN2 with this report's transcript and numbers attached.

Get the INCY recap when the next report posts

One email per quarter with the scorecard, the market reaction and what changed on the call. No account needed.

Recent INCY quarters

All INCY earnings
+2.1%FY2026 Q1

Sources

  1. FN2 corporate events calendar, resolved from the earnings calendar feed
  2. FN2 earnings calendar analyst consensus
  3. Earnings call transcript analysis, FY2026 Q1

Methodology

The report date comes from FN2's resolved corporate-events calendar and is marked estimated until the company confirms it. Consensus figures are the calendar's latest analyst estimates for the fiscal period and are not an FN2 forecast.

Risks and open questions are carried forward verbatim from FN2's structured analysis of the previous earnings call. Missing values stay missing and are never estimated.

By FN2 Research · Updated . For educational purposes only; not investment advice.